Holen Sie sich die Stockscreener-App
14.97
8.24%
-1.285
Schlusskurs vom Vortag:
$16.26
Offen:
$16.31
24-Stunden-Volumen:
59,075
Relative Volume:
0.47
Marktkapitalisierung:
$323.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-12.49%
1M Leistung:
+73.69%
6M Leistung:
+108.96%
1J Leistung:
+0.00%
1-Tages-Spanne:
$14.80
$16.39
1-Wochen-Bereich:
$14.80
$17.94
52-Wochen-Spanne:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Firmenname
Aardvark Therapeutics Inc
Sektor
Branche
Telefon
(858) 225-7696
Adresse
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Vergleichen Sie AARD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
14.90 | 352.73M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.76 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.17 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.62 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.47 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.09 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-29 | Eingeleitet | Stifel | Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Eingeleitet | BofA Securities | Buy |
| 2025-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-03-10 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
What’s the recovery path for long term holders of Aardvark Therapeutics Inc.Risk Management & Low Risk High Win Rate Picks - newser.com
Aardvark Therapeutics Inc. stock volume spike explainedTake Profit & Weekly Watchlist of Top Performers - newser.com
Using Ichimoku Cloud for Aardvark Therapeutics Inc. technicalsJuly 2025 Action & Daily Profit Focused Stock Screening - newser.com
Is Aardvark Therapeutics Inc. stock ready for breakout2025 Key Highlights & Detailed Earnings Play Strategies - newser.com
What data driven models say about Aardvark Therapeutics Inc.’s future2025 Key Highlights & AI Forecast for Swing Trade Picks - newser.com
How risky is Aardvark Therapeutics Inc. stock nowMarket Volume Report & High Accuracy Trade Signal Alerts - newser.com
Using portfolio simulators with Aardvark Therapeutics Inc. includedJuly 2025 Closing Moves & Long-Term Capital Growth Strategies - newser.com
Aardvark Therapeutics Aligns with FDA on Trial Amendment - TipRanks
Aardvark Therapeutics (NASDAQ:AARD) Receives "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome - The Manila Times
Phase 3 HERO Expanded to Ages 10+ — Aardvark Aligns with FDA on ARD-101 Trial; Readout Q3 2026 - Stock Titan
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Aardvark Therapeutics Inc a good long term investmentPrice Action Analysis & Explosive Capital Growth - earlytimes.in
Insiders Of Aardvark Therapeutics Reap Rewards After Their Investment Jumps Another US$275k - 富途牛牛
Insiders Rewarded With US$275k Addition To Investment As Aardvark Therapeutics Stock Hits US$349m - simplywall.st
Using economic indicators to assess Aardvark Therapeutics Inc. potentialQuarterly Market Summary & Verified Momentum Watchlists - newser.com
What does recent volatility data suggest for Aardvark Therapeutics Inc.Trade Risk Report & Community Verified Swing Trade Signals - newser.com
Analyzing drawdowns of Aardvark Therapeutics Inc. with statistical tools2025 Short Interest & Real-Time Volume Spike Alerts - newser.com
H.C. Wainwright Maintains Aardvark Therapeutics(AARD.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Short Interest Update - Defense World
Aardvark Therapeutics Inc. stock trend forecastWeekly Risk Report & Accurate Technical Buy Alerts - newser.com
Will Aardvark Therapeutics Inc. stock outperform international peersEarnings Performance Report & Real-Time Stock Entry Alerts - newser.com
Should you wait for a breakout in Aardvark Therapeutics Inc.Short Setup & Real-Time Chart Breakout Alerts - newser.com
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Jones Trading - Defense World
Jones Trading Initiates Coverage of Aardvark Therapeutics (AARD) with Buy Recommendation - Nasdaq
This Coinbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
JonesTrading Initiates Aardvark Therapeutics(AARD.US) With Buy Rating, Announces Target Price $33 - 富途牛牛
Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics - TipRanks
Aardvark stock slides 11% following $94M IPO - MSN
Jones Trading initiates coverage on Aardvark Therapeutics stock with Buy rating - Investing.com Nigeria
Goldman Sachs Group Inc. Purchases New Shares in Aardvark Therapeutics, Inc. $AARD - Defense World
Finanzdaten der Aardvark Therapeutics Inc-Aktie (AARD)
Es liegen keine Finanzdaten für Aardvark Therapeutics Inc (AARD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):